Gastroparesis Drugs Market by Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections), Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis, and Post-Surgical Gastroparesis), and End User (Hospitals, Pharmacies, Clinics, and E-commerce) - Global Opportunity Analysis and Industry Forecast, 2017-2023
The global gastroparesis market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023. Gastroparesis is a medical condition of the stomach, which affects the normal spontaneous movement of the muscles of the stomach. It restricts the normal digestion, causes vomiting, and problems related with blood sugar levels & nutrition. Various medications or drugs are prescribed to treat gastroparesis, such as reglan, erythromycin, antiemetics, and others.
Rise in number of surgeries, which leads to postsurgical gastroparesis conditions is the major factor that contributes to the growth of the gastroparesis drugs market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market. Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.
The global gastroparesis drugs market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is divided into prokinetic agents, antiemetic agents, and botulinum toxin injections. By disease type, it is classified into diabetic gastroparesis, idiopathic gastroparesis, postsurgical gastroparesis, and others. Depending on distribution channel, it is categorized into hospitals, pharmacies, clinics, and e-commerce. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Drug Class
Rise in number of surgeries, which leads to postsurgical gastroparesis conditions is the major factor that contributes to the growth of the gastroparesis drugs market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market. Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.
The global gastroparesis drugs market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is divided into prokinetic agents, antiemetic agents, and botulinum toxin injections. By disease type, it is classified into diabetic gastroparesis, idiopathic gastroparesis, postsurgical gastroparesis, and others. Depending on distribution channel, it is categorized into hospitals, pharmacies, clinics, and e-commerce. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global gastroparesis drugs market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
By Drug Class
- Prokinetic Agents
- Antiemetic Agents
- Botulinum Toxin Injections
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
- Post-surgical Gastroparesis
- Others
- Hospitals
- Pharmacies
- Clinics
- E-commerce
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Allergan, Plc.
- Abbott Laboratories (Abbott Arzneimittel GmbH)
- AstraZeneca Plc.
- Cadila Pharmaceuticals Ltd.
- ETX Pharma, Inc
- Evoke Pharma
- GlaxoSmithKline Plc.
- Neurogastrx, Inc.
- Valeant Pharmaceuticals International, Inc.
- Theravance Biopharma
- Altos Therapeutics LLC
- Mylan N.V.
- Hexal AG
- CEVA Group PLC
- Takeda Pharmaceutical Company Ltd
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.3. TOP PLAYER POSITIONING, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Rise in number of surgeries
3.4.1.2. Increase in the incidence rate of diabetes
3.4.1.3. Growth in geriatric population
3.4.2. Restrains
3.4.2.1. Side effects of gastroparesis drugs
3.4.2.2. Time-consuming regulatory process
3.4.3. Opportunities
3.4.3.1. Presence of untapped market
3.4.3.2. Strong pipeline for gastroparesis drugs
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
3.6. PATENT ANALYSIS
3.6.1. Patent analysis, by year
CHAPTER 4 GASTROPARESIS DRUGS MARKET, BY DRUG CLASS
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. PROKINETIC AGENTS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. ANTIEMETIC AGENTS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. BOTULINUM TOXIN INJECTIONS
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. DIABETIC GASTROPARESIS
5.2.1. Market size and forecast
5.3. IDIOPATHIC GASTROPARESIS
5.3.1. Market size and forecast
5.4. POST-SURGICAL GASTROPARESIS
5.4.1. Market size and forecast
5.5. OTHERS
5.5.1. Market size and forecast
CHAPTER 6 GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast
6.3. PHARMACIES
6.3.1. Market size and forecast
6.4. CLINICS
6.4.1. Market size and forecast
6.5. E-COMMERCE
6.5.1. Market size and forecast
CHAPTER 7 GASTROPARESIS DRUGS MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. North America gastroparesis drugs market, by country
7.2.3.1. Market size and forecast
7.2.4. U.S.
7.2.4.1. U.S. gastroparesis drugs market, by drug class
7.2.4.2. U.S. gastroparesis drugs market, by disease type
7.2.4.3. U.S. gastroparesis drugs market, by distribution channel
7.2.5. Canada
7.2.5.1. Canada gastroparesis drugs market, by drug class
7.2.5.2. Canada gastroparesis drugs market, by disease type
7.2.5.3. Canada gastroparesis drugs market, by distribution channel
7.2.6. Mexico
7.2.6.1. Mexico gastroparesis drugs market, by drug class
7.2.6.2. Mexico gastroparesis drugs market, by disease type
7.2.6.3. Mexico gastroparesis drugs market, by distribution channel
7.2.7. North America gastroparesis drugs market, by drug class
7.2.8. North America gastroparesis drugs market, by disease type
7.2.9. North America gastroparesis drugs market, by distribution channel
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Europe gastroparesis drugs market, by country
7.3.4. Market size and forecast
7.3.5. Germany
7.3.5.1. Germany gastroparesis drugs market, by drug class
7.3.5.2. Germany gastroparesis drugs market, by disease type
7.3.5.3. Germany gastroparesis drugs market, by distribution channel
7.3.6. France
7.3.6.1. France gastroparesis drugs market, by drug class
7.3.6.2. France gastroparesis drugs market, by disease type
7.3.6.3. France gastroparesis drugs market, by distribution channel
7.3.7. UK
7.3.7.1. UK gastroparesis drugs market, by drug class
7.3.7.2. UK gastroparesis drugs market, by disease type
7.3.7.3. UK gastroparesis drugs market, by distribution channel
7.3.8. Italy
7.3.8.1. Italy gastroparesis drugs market, by drug class
7.3.8.2. Italy gastroparesis drugs market, by disease type
7.3.8.3. Italy gastroparesis drugs market, by distribution channel
7.3.9. Spain
7.3.9.1. Spain gastroparesis drugs market, by drug class
7.3.9.2. Spain gastroparesis drugs market, by disease type
7.3.9.3. Spain gastroparesis drugs market, by distribution channel
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe gastroparesis drugs market, by drug class
7.3.10.2. Rest of Europe gastroparesis drugs market, by disease type
7.3.10.3. Rest of Europe gastroparesis drugs market, by distribution channel
7.3.11. Europe gastroparesis drugs market, by drug class
7.3.12. Europe gastroparesis drugs market, by disease type
7.3.13. Europe gastroparesis drugs market, by distribution channel
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Asia-Pacific gastroparesis drugs market, by country
7.4.3.1. Market size and forecast
7.4.4. Japan
7.4.4.1. Japan gastroparesis drugs market, by drug class
7.4.4.2. Japan gastroparesis drugs market, by disease type
7.4.4.3. Japan gastroparesis drugs market, by distribution channel
7.4.5. China
7.4.5.1. China gastroparesis drugs market, by drug class
7.4.5.2. China gastroparesis drugs market, by disease type
7.4.5.3. China gastroparesis drugs market, by distribution channel
7.4.6. Australia
7.4.6.1. Australia gastroparesis drugs market, by drug class
7.4.6.2. Australia gastroparesis drugs market, by disease type
7.4.6.3. Australia gastroparesis drugs market, by distribution channel
7.4.7. India
7.4.7.1. India gastroparesis drugs market, by drug class
7.4.7.2. India gastroparesis drugs market, by disease type
7.4.7.3. India gastroparesis drugs market, by distribution channel
7.4.8. South Korea
7.4.8.1. South Korea gastroparesis drugs market, by drug class
7.4.8.2. South Korea gastroparesis drugs market, by disease type
7.4.8.3. South Korea gastroparesis drugs market, by distribution channel
7.4.9. Rest of Asia-Pacific
7.4.9.1. Rest of Asia-Pacific gastroparesis drugs market, by drug class
7.4.9.2. Rest of Asia-Pacific gastroparesis drugs market, by disease type
7.4.9.3. Rest of Asia-Pacific gastroparesis drugs market, by distribution channel
7.4.10. Asia-Pacific gastroparesis drugs market, by drug class
7.4.11. Asia-Pacific gastroparesis drugs market, by disease type
7.4.12. Asia-Pacific gastroparesis drugs market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. LAMEA gastroparesis drugs market, by country
7.5.4. Market size and forecast
7.5.5. Brazil
7.5.5.1. Brazil gastroparesis drugs market, by drug class
7.5.6. Brazil gastroparesis drugs market, by disease type
7.5.6.1. Brazil gastroparesis drugs market, by distribution channel
7.5.7. Saudi Arabia
7.5.7.1. Saudi Arabia gastroparesis drugs market, by drug class
7.5.7.2. Saudi Arabia gastroparesis drugs market, by disease type
7.5.7.3. Saudi Arabia gastroparesis drugs market, by distribution channel
7.5.8. South Africa
7.5.8.1. South Africa gastroparesis drugs market, by drug class
7.5.8.2. South Africa gastroparesis drugs market, by disease type
7.5.8.3. South Africa gastroparesis drugs market, by distribution channel
7.5.9. Rest of LAMEA
7.5.9.1. Rest of LAMEA gastroparesis drugs market, by drug class
7.5.9.2. Rest of LAMEA gastroparesis drugs market, by disease type
7.5.9.3. Rest of LAMEA gastroparesis drugs market, by distribution channel
7.5.10. LAMEA gastroparesis drugs market, by drug class
7.5.11. LAMEA gastroparesis drugs market, by disease type
7.5.12. LAMEA gastroparesis drugs market, by distribution channel
CHAPTER 8 COMPANY PROFILES
8.1. ABBOTT LABORATORIES (ABBOTT ARZNEIMITTEL GMBH)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. ALLERGAN PLC
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. ASTRAZENECA PLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. CADILA PHARMACEUTICALS LIMITED
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.5. ETX PHARMA, INC.
8.5.1. Company overview
8.5.2. Company Snapshot
8.5.3. Product portfolio
8.6. EVOKE PHARMA, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product portfolio
8.6.4. Business performance
8.7. GLAXOSMITHKLINE PLC
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. NEUROGASTRX, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Product portfolio
8.9. THERAVANCE BIOPHARMA, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. VALEANT PHARMACEUTICAL INTERNATIONAL, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.3. TOP PLAYER POSITIONING, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Rise in number of surgeries
3.4.1.2. Increase in the incidence rate of diabetes
3.4.1.3. Growth in geriatric population
3.4.2. Restrains
3.4.2.1. Side effects of gastroparesis drugs
3.4.2.2. Time-consuming regulatory process
3.4.3. Opportunities
3.4.3.1. Presence of untapped market
3.4.3.2. Strong pipeline for gastroparesis drugs
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
3.6. PATENT ANALYSIS
3.6.1. Patent analysis, by year
CHAPTER 4 GASTROPARESIS DRUGS MARKET, BY DRUG CLASS
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. PROKINETIC AGENTS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. ANTIEMETIC AGENTS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. BOTULINUM TOXIN INJECTIONS
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. DIABETIC GASTROPARESIS
5.2.1. Market size and forecast
5.3. IDIOPATHIC GASTROPARESIS
5.3.1. Market size and forecast
5.4. POST-SURGICAL GASTROPARESIS
5.4.1. Market size and forecast
5.5. OTHERS
5.5.1. Market size and forecast
CHAPTER 6 GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast
6.3. PHARMACIES
6.3.1. Market size and forecast
6.4. CLINICS
6.4.1. Market size and forecast
6.5. E-COMMERCE
6.5.1. Market size and forecast
CHAPTER 7 GASTROPARESIS DRUGS MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. North America gastroparesis drugs market, by country
7.2.3.1. Market size and forecast
7.2.4. U.S.
7.2.4.1. U.S. gastroparesis drugs market, by drug class
7.2.4.2. U.S. gastroparesis drugs market, by disease type
7.2.4.3. U.S. gastroparesis drugs market, by distribution channel
7.2.5. Canada
7.2.5.1. Canada gastroparesis drugs market, by drug class
7.2.5.2. Canada gastroparesis drugs market, by disease type
7.2.5.3. Canada gastroparesis drugs market, by distribution channel
7.2.6. Mexico
7.2.6.1. Mexico gastroparesis drugs market, by drug class
7.2.6.2. Mexico gastroparesis drugs market, by disease type
7.2.6.3. Mexico gastroparesis drugs market, by distribution channel
7.2.7. North America gastroparesis drugs market, by drug class
7.2.8. North America gastroparesis drugs market, by disease type
7.2.9. North America gastroparesis drugs market, by distribution channel
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Europe gastroparesis drugs market, by country
7.3.4. Market size and forecast
7.3.5. Germany
7.3.5.1. Germany gastroparesis drugs market, by drug class
7.3.5.2. Germany gastroparesis drugs market, by disease type
7.3.5.3. Germany gastroparesis drugs market, by distribution channel
7.3.6. France
7.3.6.1. France gastroparesis drugs market, by drug class
7.3.6.2. France gastroparesis drugs market, by disease type
7.3.6.3. France gastroparesis drugs market, by distribution channel
7.3.7. UK
7.3.7.1. UK gastroparesis drugs market, by drug class
7.3.7.2. UK gastroparesis drugs market, by disease type
7.3.7.3. UK gastroparesis drugs market, by distribution channel
7.3.8. Italy
7.3.8.1. Italy gastroparesis drugs market, by drug class
7.3.8.2. Italy gastroparesis drugs market, by disease type
7.3.8.3. Italy gastroparesis drugs market, by distribution channel
7.3.9. Spain
7.3.9.1. Spain gastroparesis drugs market, by drug class
7.3.9.2. Spain gastroparesis drugs market, by disease type
7.3.9.3. Spain gastroparesis drugs market, by distribution channel
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe gastroparesis drugs market, by drug class
7.3.10.2. Rest of Europe gastroparesis drugs market, by disease type
7.3.10.3. Rest of Europe gastroparesis drugs market, by distribution channel
7.3.11. Europe gastroparesis drugs market, by drug class
7.3.12. Europe gastroparesis drugs market, by disease type
7.3.13. Europe gastroparesis drugs market, by distribution channel
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Asia-Pacific gastroparesis drugs market, by country
7.4.3.1. Market size and forecast
7.4.4. Japan
7.4.4.1. Japan gastroparesis drugs market, by drug class
7.4.4.2. Japan gastroparesis drugs market, by disease type
7.4.4.3. Japan gastroparesis drugs market, by distribution channel
7.4.5. China
7.4.5.1. China gastroparesis drugs market, by drug class
7.4.5.2. China gastroparesis drugs market, by disease type
7.4.5.3. China gastroparesis drugs market, by distribution channel
7.4.6. Australia
7.4.6.1. Australia gastroparesis drugs market, by drug class
7.4.6.2. Australia gastroparesis drugs market, by disease type
7.4.6.3. Australia gastroparesis drugs market, by distribution channel
7.4.7. India
7.4.7.1. India gastroparesis drugs market, by drug class
7.4.7.2. India gastroparesis drugs market, by disease type
7.4.7.3. India gastroparesis drugs market, by distribution channel
7.4.8. South Korea
7.4.8.1. South Korea gastroparesis drugs market, by drug class
7.4.8.2. South Korea gastroparesis drugs market, by disease type
7.4.8.3. South Korea gastroparesis drugs market, by distribution channel
7.4.9. Rest of Asia-Pacific
7.4.9.1. Rest of Asia-Pacific gastroparesis drugs market, by drug class
7.4.9.2. Rest of Asia-Pacific gastroparesis drugs market, by disease type
7.4.9.3. Rest of Asia-Pacific gastroparesis drugs market, by distribution channel
7.4.10. Asia-Pacific gastroparesis drugs market, by drug class
7.4.11. Asia-Pacific gastroparesis drugs market, by disease type
7.4.12. Asia-Pacific gastroparesis drugs market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. LAMEA gastroparesis drugs market, by country
7.5.4. Market size and forecast
7.5.5. Brazil
7.5.5.1. Brazil gastroparesis drugs market, by drug class
7.5.6. Brazil gastroparesis drugs market, by disease type
7.5.6.1. Brazil gastroparesis drugs market, by distribution channel
7.5.7. Saudi Arabia
7.5.7.1. Saudi Arabia gastroparesis drugs market, by drug class
7.5.7.2. Saudi Arabia gastroparesis drugs market, by disease type
7.5.7.3. Saudi Arabia gastroparesis drugs market, by distribution channel
7.5.8. South Africa
7.5.8.1. South Africa gastroparesis drugs market, by drug class
7.5.8.2. South Africa gastroparesis drugs market, by disease type
7.5.8.3. South Africa gastroparesis drugs market, by distribution channel
7.5.9. Rest of LAMEA
7.5.9.1. Rest of LAMEA gastroparesis drugs market, by drug class
7.5.9.2. Rest of LAMEA gastroparesis drugs market, by disease type
7.5.9.3. Rest of LAMEA gastroparesis drugs market, by distribution channel
7.5.10. LAMEA gastroparesis drugs market, by drug class
7.5.11. LAMEA gastroparesis drugs market, by disease type
7.5.12. LAMEA gastroparesis drugs market, by distribution channel
CHAPTER 8 COMPANY PROFILES
8.1. ABBOTT LABORATORIES (ABBOTT ARZNEIMITTEL GMBH)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. ALLERGAN PLC
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. ASTRAZENECA PLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. CADILA PHARMACEUTICALS LIMITED
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.5. ETX PHARMA, INC.
8.5.1. Company overview
8.5.2. Company Snapshot
8.5.3. Product portfolio
8.6. EVOKE PHARMA, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product portfolio
8.6.4. Business performance
8.7. GLAXOSMITHKLINE PLC
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. NEUROGASTRX, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Product portfolio
8.9. THERAVANCE BIOPHARMA, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. VALEANT PHARMACEUTICAL INTERNATIONAL, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 1. PATENTS REGISTERED/APPROVED IN THE WORLD, 2011-2017
TABLE 2. GLOBAL GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 3. LIST OF BRAND NAMES OF METOCLOPRAMIDE ACROSS THE WORLD
TABLE 4. GASTROPARESIS DRUGS MARKET FOR PROKINETIC AGENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GASTROPARESIS DRUGS MARKET FOR ANTIEMETIC AGENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 6. GASTROPARESIS DRUGS MARKET FOR BOTULINUM TOXIN INJECTIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 8. GASTROPARESIS DRUGS MARKET FOR DIABETIC GASTROPARESIS, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GASTROPARESIS DRUGS MARKET FOR IDIOPATHIC GASTROPARESIS, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GASTROPARESIS DRUGS MARKET FOR POST-SURGICAL GASTROPARESIS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GASTROPARESIS DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 13. GASTROPARESIS DRUGS MARKET FOR HOSPITALS, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GASTROPARESIS DRUGS MARKET FOR PHARMACIES, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GASTROPARESIS DRUGS MARKET FOR CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GASTROPARESIS DRUGS MARKET FOR E-COMMERCE, BY REGION, 2016-2023 ($MILLION)
TABLE 17. TOP 10 COUNTRIES WITH DIABETES INCIDENCE (20-79 YEARS), 2015 AND 2040
TABLE 18. GASTROPARESIS DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA GASTROPARESIS DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20. U.S. GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 21. U.S. GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 22. U.S. GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 23. CANADA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 24. CANADA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 25. CANADA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 26. MEXICO GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 27. MEXICO GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 28. MEXICO GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 31. NORTH AMERICA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 32. EUROPE GASTROPARESIS DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 33. GERMANY GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 34. GERMANY GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 35. GERMANY GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 36. FRANCE GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 37. FRANCE GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 38. FRANCE GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 39. UK GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 40. UK GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 41. UK GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 42. ITALY GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 43. ITALY GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 44. ITALY GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 45. SPAIN GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 46. SPAIN GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 47. SPAIN GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 48. REST OF EUROPE GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 49. REST OF EUROPE GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 50. REST OF EUROPE GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 51. EUROPE GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 52. EUROPE GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 53. EUROPE GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 55. JAPAN GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 56. JAPAN GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 57. JAPAN GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 58. CHINA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 59. CHINA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 60. CHINA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 61. AUSTRALIA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 62. AUSTRALIA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 63. AUSTRALIA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 64. INDIA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 65. INDIA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 66. INDIA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 67. SOUTH KOREA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 68. SOUTH KOREA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 69. SOUTH KOREA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 75. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 76. LAMEA GASTROPARESIS DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 77. BRAZIL GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 78. BRAZIL GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 79. BRAZIL GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 80. SAUDI ARABIA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 81. SAUDI ARABIA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 82. SAUDI ARABIA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 83. SOUTH AFRICA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 86. REST OF LAMEA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 87. REST OF LAMEA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 88. REST OF LAMEA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 89. LAMEA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 90. LAMEA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 91. LAMEA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 92. ABBOTT: COMPANY SNAPSHOT
TABLE 93. ABBOTT: OPERATING SEGMENTS
TABLE 94. ABBOTT: PRODUCT PORTFOLIO
TABLE 95. ALLERGAN: COMPANY SNAPSHOT
TABLE 96. ALLERGEN: OPERATING SEGMENTS
TABLE 97. ALLERGAN: PRODUCT PORTFOLIO
TABLE 98. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 99. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 100. CADILA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 101. CADILA PHARMACEUTICALS: DIVISIONS
TABLE 102. CADILA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 103. ETX PHARMA: COMPANY SNAPSHOT
TABLE 104. ETX PHARMA: PRODUCT PORTFOLIO
TABLE 105. EVOKE: COMPANY SNAPSHOT
TABLE 106. EVOKE: PRODUCT PORTFOLIO
TABLE 107. GSK: COMPANY SNAPSHOT
TABLE 108. GSK: OPERATING SEGMENTS
TABLE 109. GSK: PRODUCT PORTFOLIO
TABLE 110. NEUROGASTRX: COMPANY SNAPSHOT
TABLE 111. NEUROGASTRX: PRODUCT PORTFOLIO
TABLE 112. THERAVANCE BIOPHARMA: COMPANY SNAPSHOT
TABLE 113. THERAVANCE BIOPHARMA: PRODUCT PORTFOLIO
TABLE 114. VALEANT: COMPANY SNAPSHOT
TABLE 115. VALEANT: OPERATING SEGMENTS
TABLE 116. VALEANT: PRODUCT PORTFOLIO
TABLE 1. PATENTS REGISTERED/APPROVED IN THE WORLD, 2011-2017
TABLE 2. GLOBAL GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 3. LIST OF BRAND NAMES OF METOCLOPRAMIDE ACROSS THE WORLD
TABLE 4. GASTROPARESIS DRUGS MARKET FOR PROKINETIC AGENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GASTROPARESIS DRUGS MARKET FOR ANTIEMETIC AGENTS, BY REGION, 2016-2023 ($MILLION)
TABLE 6. GASTROPARESIS DRUGS MARKET FOR BOTULINUM TOXIN INJECTIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 8. GASTROPARESIS DRUGS MARKET FOR DIABETIC GASTROPARESIS, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GASTROPARESIS DRUGS MARKET FOR IDIOPATHIC GASTROPARESIS, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GASTROPARESIS DRUGS MARKET FOR POST-SURGICAL GASTROPARESIS, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GASTROPARESIS DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 13. GASTROPARESIS DRUGS MARKET FOR HOSPITALS, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GASTROPARESIS DRUGS MARKET FOR PHARMACIES, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GASTROPARESIS DRUGS MARKET FOR CLINICS, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GASTROPARESIS DRUGS MARKET FOR E-COMMERCE, BY REGION, 2016-2023 ($MILLION)
TABLE 17. TOP 10 COUNTRIES WITH DIABETES INCIDENCE (20-79 YEARS), 2015 AND 2040
TABLE 18. GASTROPARESIS DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA GASTROPARESIS DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20. U.S. GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 21. U.S. GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 22. U.S. GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 23. CANADA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 24. CANADA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 25. CANADA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 26. MEXICO GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 27. MEXICO GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 28. MEXICO GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 31. NORTH AMERICA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 32. EUROPE GASTROPARESIS DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 33. GERMANY GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 34. GERMANY GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 35. GERMANY GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 36. FRANCE GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 37. FRANCE GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 38. FRANCE GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 39. UK GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 40. UK GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 41. UK GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 42. ITALY GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 43. ITALY GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 44. ITALY GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 45. SPAIN GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 46. SPAIN GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 47. SPAIN GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 48. REST OF EUROPE GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 49. REST OF EUROPE GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 50. REST OF EUROPE GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 51. EUROPE GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 52. EUROPE GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 53. EUROPE GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 54. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 55. JAPAN GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 56. JAPAN GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 57. JAPAN GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 58. CHINA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 59. CHINA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 60. CHINA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 61. AUSTRALIA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 62. AUSTRALIA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 63. AUSTRALIA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 64. INDIA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 65. INDIA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 66. INDIA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 67. SOUTH KOREA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 68. SOUTH KOREA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 69. SOUTH KOREA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 75. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 76. LAMEA GASTROPARESIS DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 77. BRAZIL GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 78. BRAZIL GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 79. BRAZIL GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 80. SAUDI ARABIA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 81. SAUDI ARABIA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 82. SAUDI ARABIA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 83. SOUTH AFRICA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 86. REST OF LAMEA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 87. REST OF LAMEA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 88. REST OF LAMEA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 89. LAMEA GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($MILLION)
TABLE 90. LAMEA GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
TABLE 91. LAMEA GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
TABLE 92. ABBOTT: COMPANY SNAPSHOT
TABLE 93. ABBOTT: OPERATING SEGMENTS
TABLE 94. ABBOTT: PRODUCT PORTFOLIO
TABLE 95. ALLERGAN: COMPANY SNAPSHOT
TABLE 96. ALLERGEN: OPERATING SEGMENTS
TABLE 97. ALLERGAN: PRODUCT PORTFOLIO
TABLE 98. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 99. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 100. CADILA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 101. CADILA PHARMACEUTICALS: DIVISIONS
TABLE 102. CADILA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 103. ETX PHARMA: COMPANY SNAPSHOT
TABLE 104. ETX PHARMA: PRODUCT PORTFOLIO
TABLE 105. EVOKE: COMPANY SNAPSHOT
TABLE 106. EVOKE: PRODUCT PORTFOLIO
TABLE 107. GSK: COMPANY SNAPSHOT
TABLE 108. GSK: OPERATING SEGMENTS
TABLE 109. GSK: PRODUCT PORTFOLIO
TABLE 110. NEUROGASTRX: COMPANY SNAPSHOT
TABLE 111. NEUROGASTRX: PRODUCT PORTFOLIO
TABLE 112. THERAVANCE BIOPHARMA: COMPANY SNAPSHOT
TABLE 113. THERAVANCE BIOPHARMA: PRODUCT PORTFOLIO
TABLE 114. VALEANT: COMPANY SNAPSHOT
TABLE 115. VALEANT: OPERATING SEGMENTS
TABLE 116. VALEANT: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. GLOBAL GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 2. GASTROPARESIS DRUGS MARKET SEGMENTATION
FIGURE 3. TOP INVESTMENT POCKETS
FIGURE 4. TOP PLAYER POSITIONING, 2016
FIGURE 5. TRANSPLANTATION PERFORMED IN 2015 IN U.S.
FIGURE 6. UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
FIGURE 7. WORLD POPULATION AGED 65 AND OVER: 2015, 2030, AND 2050 (IN MILLION)
FIGURE 8. IMPACT ANALYSIS, 2016
FIGURE 9. GASTROPARESIS DRUGS MARKET: CLINICAL TRIALS
FIGURE 10. PATENTS ANALYSIS BY YEAR (2011-2017)
FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023
FIGURE 12. GLOBAL GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023
FIGURE 13. GLOBAL GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023
FIGURE 14. NORTH AMERICA GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 15. TOTAL NUMBER OF TRANSPLANTS PERFORMED IN U.S., 2017
FIGURE 16. EUROPE GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 17. PREVALENCE OF DIABETES IN EUROPEAN COUNTRIES IN ADULTS AGED 20-79 YEARS, 2010 (%)
FIGURE 18. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 19. ANNUAL TRENDS IN LIVER TRANSPLANTS IN INDIA, 2013
FIGURE 20. LAMEA GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 21. ESTIMATED NUMBER OF PEOPLE WITH DIABETES IN BRAZIL, 2013 VS. 2035 (MILLION)
FIGURE 22. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. ASTRAZENECA: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 29. GSK: REVENUE, 2014-2016 ($MILLION)
FIGURE 30. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. THERAVANCE BIOPHARMA: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. THERAVANCE BIOPHARMA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 34. VALEANT: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. VALEANT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. VALEANT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 1. GLOBAL GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 2. GASTROPARESIS DRUGS MARKET SEGMENTATION
FIGURE 3. TOP INVESTMENT POCKETS
FIGURE 4. TOP PLAYER POSITIONING, 2016
FIGURE 5. TRANSPLANTATION PERFORMED IN 2015 IN U.S.
FIGURE 6. UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
FIGURE 7. WORLD POPULATION AGED 65 AND OVER: 2015, 2030, AND 2050 (IN MILLION)
FIGURE 8. IMPACT ANALYSIS, 2016
FIGURE 9. GASTROPARESIS DRUGS MARKET: CLINICAL TRIALS
FIGURE 10. PATENTS ANALYSIS BY YEAR (2011-2017)
FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET, BY DRUG CLASS, 2016-2023
FIGURE 12. GLOBAL GASTROPARESIS DRUGS MARKET, BY DISEASE TYPE, 2016-2023
FIGURE 13. GLOBAL GASTROPARESIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023
FIGURE 14. NORTH AMERICA GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 15. TOTAL NUMBER OF TRANSPLANTS PERFORMED IN U.S., 2017
FIGURE 16. EUROPE GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 17. PREVALENCE OF DIABETES IN EUROPEAN COUNTRIES IN ADULTS AGED 20-79 YEARS, 2010 (%)
FIGURE 18. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 19. ANNUAL TRENDS IN LIVER TRANSPLANTS IN INDIA, 2013
FIGURE 20. LAMEA GASTROPARESIS DRUGS MARKET, 2016-2023
FIGURE 21. ESTIMATED NUMBER OF PEOPLE WITH DIABETES IN BRAZIL, 2013 VS. 2035 (MILLION)
FIGURE 22. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. ASTRAZENECA: NET SALES, 2014-2016 ($MILLION)
FIGURE 28. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 29. GSK: REVENUE, 2014-2016 ($MILLION)
FIGURE 30. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 31. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 32. THERAVANCE BIOPHARMA: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. THERAVANCE BIOPHARMA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 34. VALEANT: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. VALEANT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. VALEANT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
